Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Compound haploinsufficiency of Dok2 and Dusp4 promotes lung tumorigenesis.

Chen M, Zhang J, Berger AH, Diolombi MS, Ng C, Fung J, Bronson RT, Castillo-Martin M, Thin TH, Cordon-Cardo C, Plevin R, Pandolfi PP.

J Clin Invest. 2019 Jan 2;129(1):215-222. doi: 10.1172/JCI99699. Epub 2018 Nov 26.

2.

Oncogenic Signaling Pathways in The Cancer Genome Atlas.

Sanchez-Vega F, Mina M, Armenia J, Chatila WK, Luna A, La KC, Dimitriadoy S, Liu DL, Kantheti HS, Saghafinia S, Chakravarty D, Daian F, Gao Q, Bailey MH, Liang WW, Foltz SM, Shmulevich I, Ding L, Heins Z, Ochoa A, Gross B, Gao J, Zhang H, Kundra R, Kandoth C, Bahceci I, Dervishi L, Dogrusoz U, Zhou W, Shen H, Laird PW, Way GP, Greene CS, Liang H, Xiao Y, Wang C, Iavarone A, Berger AH, Bivona TG, Lazar AJ, Hammer GD, Giordano T, Kwong LN, McArthur G, Huang C, Tward AD, Frederick MJ, McCormick F, Meyerson M; Cancer Genome Atlas Research Network, Van Allen EM, Cherniack AD, Ciriello G, Sander C, Schultz N.

Cell. 2018 Apr 5;173(2):321-337.e10. doi: 10.1016/j.cell.2018.03.035.

3.

High-throughput Phenotyping of Lung Cancer Somatic Mutations.

Berger AH, Brooks AN, Wu X, Shrestha Y, Chouinard C, Piccioni F, Bagul M, Kamburov A, Imielinski M, Hogstrom L, Zhu C, Yang X, Pantel S, Sakai R, Watson J, Kaplan N, Campbell JD, Singh S, Root DE, Narayan R, Natoli T, Lahr DL, Tirosh I, Tamayo P, Getz G, Wong B, Doench J, Subramanian A, Golub TR, Meyerson M, Boehm JS.

Cancer Cell. 2017 Dec 11;32(6):884. doi: 10.1016/j.ccell.2017.11.008. No abstract available.

4.

A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles.

Subramanian A, Narayan R, Corsello SM, Peck DD, Natoli TE, Lu X, Gould J, Davis JF, Tubelli AA, Asiedu JK, Lahr DL, Hirschman JE, Liu Z, Donahue M, Julian B, Khan M, Wadden D, Smith IC, Lam D, Liberzon A, Toder C, Bagul M, Orzechowski M, Enache OM, Piccioni F, Johnson SA, Lyons NJ, Berger AH, Shamji AF, Brooks AN, Vrcic A, Flynn C, Rosains J, Takeda DY, Hu R, Davison D, Lamb J, Ardlie K, Hogstrom L, Greenside P, Gray NS, Clemons PA, Silver S, Wu X, Zhao WN, Read-Button W, Wu X, Haggarty SJ, Ronco LV, Boehm JS, Schreiber SL, Doench JG, Bittker JA, Root DE, Wong B, Golub TR.

Cell. 2017 Nov 30;171(6):1437-1452.e17. doi: 10.1016/j.cell.2017.10.049.

5.

Controlling Cooperative CO2 Adsorption in Diamine-Appended Mg2(dobpdc) Metal-Organic Frameworks.

Siegelman RL, McDonald TM, Gonzalez MI, Martell JD, Milner PJ, Mason JA, Berger AH, Bhown AS, Long JR.

J Am Chem Soc. 2017 Aug 2;139(30):10526-10538. doi: 10.1021/jacs.7b05858. Epub 2017 Jul 19.

PMID:
28669181
6.

MET Exon 14 Mutation Encodes an Actionable Therapeutic Target in Lung Adenocarcinoma.

Lu X, Peled N, Greer J, Wu W, Choi P, Berger AH, Wong S, Jen KY, Seo Y, Hann B, Brooks A, Meyerson M, Collisson EA.

Cancer Res. 2017 Aug 15;77(16):4498-4505. doi: 10.1158/0008-5472.CAN-16-1944. Epub 2017 May 18.

7.

Institutional implementation of clinical tumor profiling on an unselected cancer population.

Sholl LM, Do K, Shivdasani P, Cerami E, Dubuc AM, Kuo FC, Garcia EP, Jia Y, Davineni P, Abo RP, Pugh TJ, van Hummelen P, Thorner AR, Ducar M, Berger AH, Nishino M, Janeway KA, Church A, Harris M, Ritterhouse LL, Campbell JD, Rojas-Rudilla V, Ligon AH, Ramkissoon S, Cleary JM, Matulonis U, Oxnard GR, Chao R, Tassell V, Christensen J, Hahn WC, Kantoff PW, Kwiatkowski DJ, Johnson BE, Meyerson M, Garraway LA, Shapiro GI, Rollins BJ, Lindeman NI, MacConaill LE.

JCI Insight. 2016 Nov 17;1(19):e87062. doi: 10.1172/jci.insight.87062.

8.

High-throughput Phenotyping of Lung Cancer Somatic Mutations.

Berger AH, Brooks AN, Wu X, Shrestha Y, Chouinard C, Piccioni F, Bagul M, Kamburov A, Imielinski M, Hogstrom L, Zhu C, Yang X, Pantel S, Sakai R, Watson J, Kaplan N, Campbell JD, Singh S, Root DE, Narayan R, Natoli T, Lahr DL, Tirosh I, Tamayo P, Getz G, Wong B, Doench J, Subramanian A, Golub TR, Meyerson M, Boehm JS.

Cancer Cell. 2016 Aug 8;30(2):214-228. doi: 10.1016/j.ccell.2016.06.022. Epub 2016 Jul 28. Erratum in: Cancer Cell. 2017 Dec 11;32(6):884.

9.

Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas.

Campbell JD, Alexandrov A, Kim J, Wala J, Berger AH, Pedamallu CS, Shukla SA, Guo G, Brooks AN, Murray BA, Imielinski M, Hu X, Ling S, Akbani R, Rosenberg M, Cibulskis C, Ramachandran A, Collisson EA, Kwiatkowski DJ, Lawrence MS, Weinstein JN, Verhaak RG, Wu CJ, Hammerman PS, Cherniack AD, Getz G; Cancer Genome Atlas Research Network, Artyomov MN, Schreiber R, Govindan R, Meyerson M.

Nat Genet. 2016 Jun;48(6):607-16. doi: 10.1038/ng.3564. Epub 2016 May 9.

10.

The role of C1q in recognition of apoptotic epithelial cells and inflammatory cytokine production by phagocytes during Helicobacter pylori infection.

Fox S, Ryan KA, Berger AH, Petro K, Das S, Crowe SE, Ernst PB.

J Inflamm (Lond). 2015 Sep 8;12:51. doi: 10.1186/s12950-015-0098-8. eCollection 2015.

11.

Inpatient versus outpatient vincristine, dactinomycin, and cyclophosphamide for pediatric cancers: Quality and cost implications.

Beaty RS, Bernhardt MB, Berger AH, Hesselgrave JE, Russell HV, Okcu MF.

Pediatr Blood Cancer. 2015 Nov;62(11):1925-8. doi: 10.1002/pbc.25610. Epub 2015 Jul 7.

PMID:
26152314
12.

Suppression of CHK1 by ETS Family Members Promotes DNA Damage Response Bypass and Tumorigenesis.

Lunardi A, Varmeh S, Chen M, Taulli R, Guarnerio J, Ala U, Seitzer N, Ishikawa T, Carver BS, Hobbs RM, Quarantotti V, Ng C, Berger AH, Nardella C, Poliseno L, Montironi R, Castillo-Martin M, Cordon-Cardo C, Signoretti S, Pandolfi PP.

Cancer Discov. 2015 May;5(5):550-63. doi: 10.1158/2159-8290.CD-13-1050. Epub 2015 Feb 4.

13.

Brain angiogenesis inhibitor 1 is expressed by gastric phagocytes during infection with Helicobacter pylori and mediates the recognition and engulfment of human apoptotic gastric epithelial cells.

Das S, Sarkar A, Ryan KA, Fox S, Berger AH, Juncadella IJ, Bimczok D, Smythies LE, Harris PR, Ravichandran KS, Crowe SE, Smith PD, Ernst PB.

FASEB J. 2014 May;28(5):2214-24. doi: 10.1096/fj.13-243238. Epub 2014 Feb 7.

14.

Oncogenic RIT1 mutations in lung adenocarcinoma.

Berger AH, Imielinski M, Duke F, Wala J, Kaplan N, Shi GX, Andres DA, Meyerson M.

Oncogene. 2014 Aug 28;33(35):4418-23. doi: 10.1038/onc.2013.581. Epub 2014 Jan 27.

15.

BCR-ABL disrupts PTEN nuclear-cytoplasmic shuttling through phosphorylation-dependent activation of HAUSP.

Morotti A, Panuzzo C, Crivellaro S, Pergolizzi B, Familiari U, Berger AH, Saglio G, Pandolfi PP.

Leukemia. 2014 Jun;28(6):1326-33. doi: 10.1038/leu.2013.370. Epub 2013 Dec 9.

PMID:
24317448
16.

DOK2 inhibits EGFR-mutated lung adenocarcinoma.

Berger AH, Chen M, Morotti A, Janas JA, Niki M, Bronson RT, Taylor BS, Ladanyi M, Van Aelst L, Politi K, Varmus HE, Pandolfi PP.

PLoS One. 2013 Nov 8;8(11):e79526. doi: 10.1371/journal.pone.0079526. eCollection 2013.

17.

Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing.

Imielinski M, Berger AH, Hammerman PS, Hernandez B, Pugh TJ, Hodis E, Cho J, Suh J, Capelletti M, Sivachenko A, Sougnez C, Auclair D, Lawrence MS, Stojanov P, Cibulskis K, Choi K, de Waal L, Sharifnia T, Brooks A, Greulich H, Banerji S, Zander T, Seidel D, Leenders F, Ansén S, Ludwig C, Engel-Riedel W, Stoelben E, Wolf J, Goparju C, Thompson K, Winckler W, Kwiatkowski D, Johnson BE, Jänne PA, Miller VA, Pao W, Travis WD, Pass HI, Gabriel SB, Lander ES, Thomas RK, Garraway LA, Getz G, Meyerson M.

Cell. 2012 Sep 14;150(6):1107-20. doi: 10.1016/j.cell.2012.08.029.

18.

Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2.

Greulich H, Kaplan B, Mertins P, Chen TH, Tanaka KE, Yun CH, Zhang X, Lee SH, Cho J, Ambrogio L, Liao R, Imielinski M, Banerji S, Berger AH, Lawrence MS, Zhang J, Pho NH, Walker SR, Winckler W, Getz G, Frank D, Hahn WC, Eck MJ, Mani DR, Jaffe JD, Carr SA, Wong KK, Meyerson M.

Proc Natl Acad Sci U S A. 2012 Sep 4;109(36):14476-81. doi: 10.1073/pnas.1203201109. Epub 2012 Aug 20.

19.

In silico screening of carbon-capture materials.

Lin LC, Berger AH, Martin RL, Kim J, Swisher JA, Jariwala K, Rycroft CH, Bhown AS, Deem MW, Haranczyk M, Smit B.

Nat Mater. 2012 May 27;11(7):633-41. doi: 10.1038/nmat3336.

PMID:
22635045
20.

Dosage and tumour suppression.

Berger AH, Knudson AG, Pandolfi PP.

J Pathol. 2012 Jun;227(2):e1; author reply e2. doi: 10.1002/path.4035. No abstract available.

PMID:
22488586
21.

A continuum model for tumour suppression.

Berger AH, Knudson AG, Pandolfi PP.

Nature. 2011 Aug 10;476(7359):163-9. doi: 10.1038/nature10275. Review.

22.

Haplo-insufficiency: a driving force in cancer.

Berger AH, Pandolfi PP.

J Pathol. 2011 Jan;223(2):137-46. doi: 10.1002/path.2800. Epub 2010 Oct 29. Review.

PMID:
21125671
23.

Identification of DOK genes as lung tumor suppressors.

Berger AH, Niki M, Morotti A, Taylor BS, Socci ND, Viale A, Brennan C, Szoke J, Motoi N, Rothman PB, Teruya-Feldstein J, Gerald WL, Ladanyi M, Pandolfi PP.

Nat Genet. 2010 Mar;42(3):216-23. doi: 10.1038/ng.527. Epub 2010 Feb 7.

24.

Animal-to-Human Transplants: The Ethics of Xenotransplantation: a review.

Berger AH.

Sci Eng Ethics. 1996 Oct;2(4):481-2. No abstract available.

PMID:
11657734

Supplemental Content

Loading ...
Support Center